Syngene International Ltd Share Price

Miscellaneous - Large

NSE: SYNGENE Mid Cap ISIN: INE398R01022

As on 31 January 2025 at 14:19 IST

₹741.90

-17.80

(-2.34%)

Sell Buy

About Syngene International Ltd

Syngene International Ltd is a contract research and manufacturing organization (CRMO). It provides integrated research, development, and manufacturing services. These services are globally offered for pharmaceutical, biotechnology, nutrition, and speciality chemical companies. The company was founded in 1993. Syngene International has grown to become one of India's leading CRAMS players with prestigious international clients. The headquarters of the company is located in Bangalore, Karnataka. Syngene's main services include integrated drug discovery, dedicated R&D centres, biologics manufacturing, small molecule development, and clinical development services. The company operates in the Healthcare Services sector. Read More...

Over 1 Month

-11.55%

Over 6 Months

-4.28%

Over 1 Year

5.98%

Over 3 Years

33.26%

Syngene International Ltd Summary

Close ₹ 741.90

Open ₹ 756.60

High ₹ 767.20

Low ₹ 739.05

Volume 3,25,011

Net Turnover (in ₹ Cr) ₹ 25.76

52Wk High ₹ 960.60

52Wk Low ₹ 607.65

52Wk High / Low

607.65

960.60

Syngene International Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 30,580.73

EPS (TTM) 11.41

Book Value (BV) 107.28

Div. Yield 0.16 %

P/E (TTM) 63.15

Price/Book Value 7.07

Delivery % 49.89 %

Face Value 10

Key Ratios

PE Ratio 60.49

PB Ratio 6.73

EV to Sales 8.75

PEG Ratio -39.59

ROA 9.71

ROE 11.95

Debt-Equity 0.12

Net Profit Margin 14.56

Operating Profit Margin 29.84

Syngene International Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	3,579.20	3,263.80	2,657	2,248.90	2,093.50
Total Expenses	2,947.30	2,670.20	2,141.90	1,814.70	1,647.90
Profit Before Tax	620.80	593.60	484.40	469.20	516.90
Profit After Tax	510	464.40	395.80	404.90	412.10
Operating Profit after Depreciation	679.10	638.80	539.20	461.90	480.20

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	2,810.20	2,618.80	2,354.30	2,163.40	1,983.70
Total Non Current Assets	4,192.60	3,405.70	3,357.90	3,076.50	2,550.30
Total Current Assets	1,959	2,425.30	2,205.90	1,806.70	1,612.60
TOTAL ASSETS	6,151.60	5,831	5,563.80	4,883.20	4,162.90
Total Shareholder's Fund	4,257.80	3,618	3,297.60	2,821.40	2,175.80

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	1,042.10	823.50	580.60	701.20	677.10
Net Cash used in Investing Activities	-494.40	-653.30	-610.80	-628.90	-423.80
Net Cash used in Financing Activities	-551.50	-342.50	-31.30	58	-225.50

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	3,291.10	3,264.40	2,709	2,244	2,093.50
Total Expenses	2,722.70	2,663.50	2,196.60	1,811.60	1,649.10
Profit Before Tax	557.30	600.90	481.70	467.40	515.70
Profit After Tax	466.50	473	393.80	403.70	411.50
Operating Profit after Depreciation	597.90	646.10	536.50	460.10	479

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	2,278.10	2,211.80	2,354.30	2,163.40	1,983.70
Total Non Current Assets	3,982	2,963.70	3,357.20	3,076.50	2,550.60
Total Current Assets	1,851.90	2,884.30	2,203.60	1,801	1,611.40
TOTAL ASSETS	5,833.90	5,848	5,560.80	4,877.50	4,162
Total Shareholder's Fund	4,191.50	3,618.90	3,292	2,818.30	2,174.10

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	913.40	838.40	582.20	698	677.40
Net Cash used in Investing Activities	-382.60	-685.10	-610.80	-628.90	-423.80
Net Cash used in Financing Activities	-536.30	-340.20	-31.30	58	-225.50

Particulars (in ₹ Cr.)	2024-12	2024-09	2024-06	2024-03	2023-12
Total Revenue	943.70	891	789.70	916.90	853.50
Total Expenses	660.10	646.20	619.90	600	622
Profit Before Tax	180.80	137.30	101.30	209	138.20
Profit After Tax	131.10	106.10	75.70	188.60	111.50
Operating Profit after Depreciation	301.90	261.30	187.90	333	260.80

Particulars (in ₹ Cr.)	2024-12	2024-09	2024-06	2024-03	2023-12
Total Revenue	877.10	821.30	726.50	864.70	791.90
Total Expenses	626.30	612.70	578.30	565.40	592.40
Profit Before Tax	169.80	124.30	98.80	210.40	124.70
Profit After Tax	123.10	96.60	73.90	189.80	99.80
Operating Profit after Depreciation	268.80	225	165.90	314.60	228.30

Syngene International Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 754.12

S2 748.53

S3 744.47

Pivot 758.18

R1 763.77

R2 767.83

R3 773.42

Moving Average

20 SMA 823.27

50 SMA 858.84

100 SMA 871.04

200 SMA 807.60

Syngene International Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Syngene International Ltd

₹1.25/Share

Announcement Date 28 Jun 2024

Record Date 28 Jun 2024

Div Yield 12.5%

AGM Date: 20 Jul 2022

Outcome of the Board Meeting Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the copies of newspaper advertisement published in Financial Express (English Language) and Vijayavani (Kannada Language), in compliance with Ministry of Corporate Affairs Circular No. 20/2020 dated May 5, 2020, intimating that the 29th Annual General Meeting of the Company will be held on Wednesday, July 20, 2022 at 3:30 pm IST through Video Conferencing (VC) / Other Audio Visual Means (OAVM).The above information will also be available on the website of the Company at www.syngeneintl.com. Request you to kindly take this intimation on record and acknowledge. (As Per BSE Announcement Dated on 27/06/2022) In continuation to our letter dated June 27, 2022 on Notice of the 29th AGM, we wish to inform you that the Company has completed dispatching of Notice of the 29th AGM and Annual Report 2021-22 through e-mail on June 27, 2022 to eligible members who have registered their e-mail ID's with the Company/Depositories. Please find enclosed the copies of newspaper advertisement published in Financial Express (English Language) on June 28, 2022 and Vijayavani, Bengaluru Edition (Kannada Language) on June 28, 2022 (As Per BSE Announcement Dated on 28.06.2022) Corrigendum to the Annual Report for FY 2021-22. (As Per BSE Announcement Dated on 06.07.2022) Syngene International Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement Dated on 22.07.2022) With reference to the above-mentioned subject, we hereby enclose the proceedings of the 29th Annual General Meeting ('AGM') held on Wednesday, July 20, 2022 at 03:30 p.m. through video conferencing. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the shareholders at the 29th Annual General Meeting ('AGM') held on July 20, 2022 approved the re-appointment of Ms. Sharmila Abhay Karve (DIN: 05018751) as the Independent Director on the Board of Directors of the Company, for a second term of five years commencing from the date of 29th AGM i.e. July 20, 2022. The consolidated Scrutinizer's Report on the remote e-voting and voting through Insta-poll on 29th AGM held on July 20, 2022. Voting results under Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement Dated 21.07.2022)

AGM Date: 26 Jul 2023

Cconvening of the 30th Annual General Meeting of the Company on Wednesday, July 26, 2023 We wish to inform you that the Company has completed dispatching of Notice of the 30th AGM and Annual Report 2022-23 through email on July 4,2023 to eligible members who have registered their email ID''s with the Company / Depository Participant(s) . Please find enclosed the copies of the newspaper advertisement published in Financial Express (English language) on July 5,2023 and Vijayavani, Bengaluru edition (Kannada Language) on July 5,2023. (As Per BSE Announcement Dated on 05.07.2023) Proceedings of the 30th Annual General Meeting. (As per BSE Announcement Dated on 26/07/2023) The Consolidated Scrutinizer''s Report on the remote e-voting and voting through Insta-poll 30th AGM on July 26, 2023. Voting Results under Regulation 44(3) of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. (As Per BSE Announcement Dated on 28.07.2023)

AGM Date: 24 Jul 2024

Convening of the 31st Annual General Meeting of the Company on Wednesday, July 24, 2024. Copy of the notice convening the Annual General Meeting will be sent in due course Notice of the 31st Annual General Meting ('AGM') (As Per BSE Announcement Dated on: 02/07/2024) Proceedings of the 31st Annual General Meeting. (As Per BSE Announcement Dated on: 24/07/2024)

Syngene International Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Syngene International Ltd	₹758.45	₹30,530.42
Max Healthcare Institute Ltd	₹1,042.60	₹1,01,354.49
Apollo Hospitals Enterprise Ltd	₹6,827.55	₹98,169.69
Fortis Healthcare Ltd	₹648.40	₹48,951.49
Global Health Ltd	₹1,048	₹28,147.96
Narayana Hrudayalaya Ltd	₹1,302.75	₹26,623.10

Syngene International Ltd News

Syngene Intl drops on lowering FY25 guidance; Q3 PAT jumps 17% YoY

Syngene International slumped 6.17% to Rs 795 after the company projected single-digit revenue growth and flat profit after tax (PAT) for the full year, with unchanged EBITDA guidance.

24 Jan 2025, 04:13 pm

Syngene International to announce Quarterly Result

On 23 January 2025

13 Jan 2025, 05:29 pm

Volumes jump at Syngene International Ltd counter

Syngene International Ltd witnessed volume of 83.86 lakh shares by 10:46 IST on BSE, a 342.87 times surge over two-week average daily volume of 24459 shares

10 Dec 2024, 11:00 am

Board of Syngene International approves change in management

At meeting held on 23 October 2024

23 Oct 2024, 03:34 pm

Syngene International to convene board meeting

On 23 October 2024

05 Oct 2024, 10:06 am

Syngene International Ltd Stock Analysis

Annual revenue for Syngene International Ltd increased by 0.82% to ₹3,291.10 crore in FY 2024 from ₹3,264.40 crore in FY 2023.
Annual Net Profit for Syngene International Ltd decreased by 1.37% to ₹466.50 crore in FY 2024 from ₹473 crore in FY 2023.
Promoter Shareholding in Syngene International Ltd decreased by 3.63% in the most recent quarter, from 54.72% in September 2024 to 52.74% in December 2024.
Syngene International Ltd delivered a 1-year return of 5.98% compared to the Nifty 50, which provided a return of 8.03% as of the last trading session.
Syngene International Ltd share price moved down by 2.34% from its previous close of INR ₹759.70. The latest Syngene International Ltd share price is INR ₹741.90.
Syngene International Ltd share price today has been at a low of 739.05 and a high of 767.20. Over the past 52 weeks, the Syngene International Ltd share price has seen a low of 607.65 and a high of 960.60.

About Syngene International Ltd

Syngene International Ltd is a contract research and manufacturing organization (CRMO). It offers these services for pharmaceutical, nutrition, animal health, and speciality chemical companies. The company provides integrated research, development, and manufacturing services globally. The company falls under the Healthcare Services sector. Syngene specifically focuses on the Contract Research & Manufacturing Services (CRAMS) subsector.

Initiated in 1993, Syngene has been in business for many years. The company is headquartered in Bangalore, Karnataka, India. Syngene was promoted by Biocon Ltd, with Dr. Kiran Mazumdar-Shaw playing a pivotal role in its establishment and growth. Also, he serves as the non-executive chairman of the company. The company is guided by an experienced board of directors. The managerial promoters of the company include:

Jonathan Hunt
Sibaji Biswas
Catherine Rosenberg
Kush Parmar

The promoter shareholding of the company stands at 54.72%. Biocon remains the principal promoter of the company, holding a 54.45% stake in the company.

The main services offered by Syngene include integrated drug discovery services, dedicated R&D centres and biologics manufacturing. It also offers small molecule development manufacturing and clinical development services. The company operates state-of-the-art research facilities that cater to global pharmaceutical giants.

Syngene is among the leading players in India's CRAMS sector. However, it is not the top player in terms of market capitalization. The company has established itself as one of the most respected names in the industry, with a strong global client base. This includes Bristol Myers Squibb, Amgen, and GSK.

The company's registered office is located at Biocon Park, Bommasandra Industrial Area, Phase IV, Bangalore - 560099, Karnataka. The registrar and transfer agent for Syngene is KFin Technologies Limited.

International Base of the Company

Syngene International Ltd. has established itself as a prominent global contract research and manufacturing organization. The company serves its clients across many continents. Since its start in 1993, the company has systematically built its international presence by focusing on delivering high-quality research, development, and manufacturing services to pharmaceutical and biotechnology companies worldwide.

The company's international footprint is primarily demonstrated through its impressive client roster. This includes several global pharmaceutical giants. Bristol Myers Squibb is one of the world's largest pharmaceutical companies. It has had a long-standing relationship with Syngene, operating a dedicated research facility in Bangalore. The partnership of these companies began in 2007 and has grown significantly. This showcases Syngene's ability to meet international quality standards and regulatory requirements.

Syngene International has collaboration with Amgen and another major global biotechnology company. This further strengthens its international credentials. The company operates a dedicated R&D centre for Amgen, providing integrated drug discovery and development services. This partnership demonstrates Syngene's capability to handle complex research projects and meet the exacting standards of international clients.

The company's relationship with GlaxoSmithKline (GSK) represents another significant international partnership. Through this collaboration, Syngene provides various research and development services. This contributes to GSK's global drug discovery and development programs. These partnerships with leading pharmaceutical companies have helped Syngene build a strong reputation in the global CRAMS market.

Syngene's international operations are supported by its state-of-the-art facilities in India that conform to global standards. The company's research and manufacturing facilities are certified by international regulatory authorities. These authorities include the US FDA and EMA (European Medicines Agency), which enables the company to serve its clients worldwide. This regulatory compliance has been crucial in attracting and retaining international clients.

The company has also developed expertise in various therapeutic areas that are relevant to global markets. These therapeutic areas include oncology, cardiovascular, diabetes, and inflammatory diseases. This broad therapeutic coverage allows Syngene to cater to diverse international client requirements and participate in global drug discovery and development programs.

Syngene's international business model is built on providing integrated services across the drug discovery and development value chain. The company offers end-to-end solutions from early-stage research to commercial manufacturing. These solutions appeal to international clients looking to outsource their R&D and manufacturing needs. This comprehensive service offering has helped Syngene secure long-term contracts with international clients.

The company's scientific talent pool comprises highly qualified researchers and scientists. Many of these researchers and scientists have international exposure and experience, which further strengthens the company's ability to serve global clients. This expertise allows Syngene to undertake complex research projects and deliver results that meet international standards.

Syngene International's success in building a strong international presence can be attributed to its focus on quality, regulatory compliance, comprehensive service offerings, and strong client relationships. The company has successfully positioned itself as a reliable partner for global pharmaceutical and biotechnology companies. This is evidenced by its long-term partnerships with industry leaders like Bristol Myers Squibb, Amgen, and GSK.

Plus, the company is committed to maintaining high-quality standards and investing in cutting-edge facilities. This suggests that it will continue to strengthen its position in the global CRAMS market. The company's international focus has helped to grow its business. Also, this has also contributed to establishing India as a preferred destination for pharmaceutical research and manufacturing services.